22:32 , Dec 18, 2017 |  BC Extra  |  Company News

China's RDPAC names executive committee

China's R&D-based Pharmaceutical Association Committee, a non-profit organization made up of 41 multinational biopharmaceutical companies, named 13 members to its 2018-19 executive committee. Appointees include Jean-Christophe Pointeau as chairman and Hong Chow, Renaud Gabay and...
21:13 , Oct 13, 2017 |  BC Week In Review  |  Clinical News

Athera begins Phase IIa trial of PC-mAb for arterial inflammation

Athera Biotechnologies AB (Stockholm, Sweden) began a Phase IIa trial of once-monthly IV PC-mAb to treat arterial inflammation in patients with elevated levels of lipoprotein(a) (LPA) . The double-blind, placebo-controlled, European trial's primary endpoint is...
08:00 , Jan 25, 2016 |  BioCentury  |  Strategy

Formative years

VCs that spend a large chunk of their time and capital creating companies from scratch are planning to continue regardless of what happens with the financial markets. Although de novo company formation takes a lot...
01:34 , Mar 11, 2015 |  BC Extra  |  Company News

Pernix acquires Zogenix's Zohydro franchise

Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) will acquire the Zohydro ER analgesic franchise of Zogenix Inc. (NASDAQ:ZGNX). The franchise includes Zohydro ER, an oral controlled-release formulation of hydrocodone; Zohydro ER with BeadTek , an oral controlled-release...
08:00 , Feb 16, 2015 |  BioCentury  |  Politics, Policy & Law

Start the experiments

It is at least beginning to dawn on all but the most obstinate of companies that current drug pricing paradigms are unsustainable. Yet barriers created by long-standing Medicare and Medicaid rules - some real and...
08:00 , Feb 12, 2015 |  BC Innovations  |  Targets & Mechanisms

High five for Arsanis

Researchers at Arsanis Inc. and Adimab LLC have identified an antibody that simultaneously neutralizes five Staphylococcus aureus toxins - defying the odds of hitting such diverse structures by fishing out an exposed conserved patch. While...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Athera, Boehringer Ingelheim deal

Athera said Boehringer declined to exercise its exclusive, 2013 option to PC-mAb , a human mAb against phosphorylcholine that is in Phase I testing to treat patients with cardiovascular disease at an increased risk for...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Company News

Accel-Rx Health Sciences Accelerator finance news

Accel-Rx, a pan-Canadian health sciences accelerator, announced its official launch after receiving a C$14.5 million ($13.1 million) award from the Canadian government's Centers of Excellence for Commercialization and Research (CECR) program. CDRD Ventures Inc. ,...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

Orteronel: Development discontinued

Takeda discontinued development of orteronel for prostate cancer after reporting mixed Phase III data in metastatic CRPC. Takeda said orteronel did not demonstrate a clinical profile “sufficient” to move forward in the indication “given the...
07:00 , Jun 2, 2014 |  BioCentury  |  Strategy

Reforming oncology

The American Society of Clinical Oncology has made drug prices and value a centerpiece of its annual meeting this week, but its newly unveiled payment model doesn't yet address how physician practices actually should be...